BioSpace News Archive

Outlook Therapeutics, Inc. today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.

Ocuphire Pharma, Inc. today announced that it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM).

Gala Therapeutics, Inc. today announced the first worldwide commercial procedures using the RheOx ® Bronchial Rheoplasty system.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company’s business and outlook on Tuesday, Feb. 22 , at 4:30 p.m. ET .

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced the closing of a US$50 million, tranched, series A financing.

Researchers from National Institute of Standards and Technology, Baylor College of Medicine and DNAnexus, Inc., together with other members of the Genome in a Bottle consortium, announce the publication of a comprehensive benchmark dataset comprising 273 challenging medically relevant autosomal genes that are associated with the development of diseases such as homocystinuria and spinal muscular atrophy.

Blackrock Neurotech, the leader in brain-computer interface technology, has signed an exclusive license for Columbia University’s neural decoder MINT.

Trinity Life Sciences, a leader in global life sciences solutions, conducted research to explore the importance and impact of Competitive Intelligence (CI) from the perspective of pharma clinical and commercial teams.

Pulse Biosciences, Inc. today announced an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System’s current labeling.

INmune Bio, Inc. announced that Raymond J. Tesi, MD, President and CEO, will present at the BIO CEO & Investor Conference being held February 14 – 17 at the Marriott Marquis in New York City.